Cingulate raises $11.7M, extends cash runway through Q2 2025; NDA for CTx-1301 targeted mid-2025

Cingulate Inc.

Raised approximately $11.7 million in capital during August and September 2024.
Cash and cash equivalents of approximately $10 million as of September 30, 2024.
Cash runway extended through second quarter of 2025 to fund clinical, manufacturing, and regulatory activities.
NDA filing for CTx-1301 targeting mid-2025 for potential FDA approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.